Small Molecule KRAS Agonist for Mutant KRAS Cancer Therapy

BACKGROUND: Lung cancer patients with KRAS mutation(s) have a poor prognosis due in part to the development of resistance to currently available therapeutic interventions. Development of a new class of anticancer agents that directly targets KRAS may provide a more attractive option for the treatmen...

Descripción completa

Detalles Bibliográficos
Autores principales: Xu, Ke, Park, Dongkyoo, Magis, Andrew T., Zhang, Jun, Zhou, Wei, Sica, Gabriel L., Ramalingam, Suresh S., Curran, Walter J., Deng, Xingming
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2019
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6456974/
https://www.ncbi.nlm.nih.gov/pubmed/30971271
http://dx.doi.org/10.1186/s12943-019-1012-4

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6456974/
https://www.ncbi.nlm.nih.gov/pubmed/30971271
http://dx.doi.org/10.1186/s12943-019-1012-4

Ejemplares similares